A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Inclusion Criteria

• •Subjects must satisfy the following criteria to be enrolled in the study:
• •1. Subject is a male, or a non-pregnant and non-nursing female between 18 and 55 years, inclusive, of age at the time of signing the Informed Consent Form (ICF).
• •2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
• •3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
• •4. Subject has a BMI ≥ 18 and ≤ 33 kg/m2 at screening.
• •5. Female subject
• •1. Must have a negative pregnancy test
• •2. If postmenopausal: must have follicular stimulating hormone (FSH) test result \>40 IU/L and a negative pregnancy test
• •6. Contraception Requirements:
• •Must comply with the following acceptable forms of contraception. All females of childbearing potential (FCBP) must use one of the approved contraceptive2 options described below while taking CC-11050 and for at least 28 days after administration of the CC-11050 dose. At the time of study entry, and at any time during the study when a FCFP's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy. A FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below: Option 1: One highly effective method (eg, hormonal contraception \[oral, injection, implant, transdermal patch, vaginal ring\]; intrauterine device; tubal ligation; or partner's vasectomy) and 1 additional form (latex condom or any nonlatex condom not made of natural \[animal\] membrane \[eg, polyurethane\], diaphragm, sponge).
• •OR Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural \[animal\] membrane \[for example, polyurethane) PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
• •7. A male subject must:
• •a. Practice true abstinence3 (which must be reviewed on a monthly basis and source documented) or agree to use a barrier method of birth control (condoms not made out of natural \[animal\] membrane \[latex condoms are recommended\]) during sexual contact with a pregnant female or female of FCBP while participating in the study, during dose interruptions, and for at least 28 days after the dose of IP, even if he has undergone a successful vasectomy.
• •8. Subject has clinical laboratory safety test results that are within normal limits (WNL) or acceptable to the Investigator.
• •9. Subject is afebrile (febrile is defined as ≥ 38°C or ≥100.4°F), with supine systolic blood pressure ≥ 90 and ≤ 150 mm Hg, supine diastolic blood pressure ≥ 50 and ≤ 90 mm Hg, and pulse rate ≥ 40 and ≤ 100 beats per minute at screening
• •10. Subject is in good health as determined by past medical history, PE, vital signs, 12-lead ECG, and clinical laboratory safety tests. Clinical laboratory safety tests (ie, hematology, chemistry, and urinalysis) and 12-lead ECGs must be WNL or clinically acceptable as judged by the Investigator.
• •11. Subject has a normal or clinically acceptable 12-lead ECG at screening. In addition:
• •* If male, the subject has a QTcF value ≤ 450 msec at screening
• •* If female, the subject has a QTcF value ≤ 470 msec at screening